Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution

Pigment Cell and Melanoma Research

Volumn 23, Issue 5, 2010, Pages

  Bonnet, M ^a   Mishellany, F ^b   Papon, J ^b,c   Cayre, A ^b   Penault Llorca, F ^a   Madelmont, J C ^a   Miot Noirault, E ^a   Chezal, J M ^a   Moins, N ^a  

^a INSERM   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

internal radionuclide therapy; melanin; melanoma; radiopharmaceuticals

Indexed keywords

CF 01012; IODINE 125; IODINE 131; MELANIN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL STRUCTURE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOPHAGE; MITOSIS INDEX; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN LOCALIZATION; TARGETED INTERNAL RADIONUCLIDE THERAPY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; ULTRASTRUCTURE ANALYSIS AND ELECTRON MICROSCOPY; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; HUMANS; IODINE RADIOISOTOPES; MALE; MELANINS; MELANOMA; MELANOSOMES; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; PIGMENTATION; QUINOXALINES; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77956330138     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00716.x     Document Type: Article

References (40)

1. Agarwala, S.S. (2009). Current systemic therapy for metastatic melanoma. Expert Rev. Anticancer Ther. 9, 587 595.
2. Bedikian, A.Y., Millward, M., Pehamberger, H. et al. (2006). Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24, 4738 4745.
3. Bonnet-Duquennoy, M., Papon, J., Mishellany, F. et al. (2009). Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent. Int. J. Cancer 125, 708 716.
4. Carlson, J.A., Linette, G.P., Aplin, A., Ng, B. Slominski, A. (2007). Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol. Clin. 25, 541 557. viii-ix.
5. Chezal, J.M., Papon, J., Labarre, P. et al. (2008). Evaluation of radiolabeled hetero)aromatic analogues of N-(2-diethylaminoethyl)4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J. Med. Chem. 51, 3133 3144.
6. Dadachova, E., Revskaya, E., Sesay, M.A. et al. (2008). Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol. Ther. 7, 1116 1127.
7. Denoyer, D., Papon, J., Miot-Noirault, E., Galmier, M.J., Madelmont, J.C., Chezal, J.M. Moins, N. (2008). Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent. J. Chromatogr. B 875, 411.
8. Djordjevic, B. (2000). Bystander effects: a concept in need of clarification. Bioessays 22, 286 290.
9. Eigentler, T.K., Caroli, U.M., Radny, P. Garbe, C. (2003). Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 4, 748 759.
10. Eisenhut, M., Hull, W.E., Mohammed, A., Mier, W., Lay, D., Just, W., Gorgas, K., Lehmann, W.D. Haberkorn, U. (2000). Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J. Med. Chem. 43, 3913 3922.
11. Fecher, L.A., Amaravadi, R.K. Flaherty, K.T. (2008). The MAPK pathway in melanoma. Curr. Opin. Oncol. 20, 183 189.
12. Garbe, C. Eigentler, T.K. (2007). Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 17, 117 127.
13. Garbe, C. Leiter, U. (2009). Melanoma epidemiology and trends. Clin. Dermatol. 27, 3 9.
14. Gray-Schopfer, V., Wellbrock, C. Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851 857.
15. Hall, E.J. (2003). The bystander effect. Health Phys. 85, 31 35.
16. Jennings, L. Murphy, G.M. (2009). Predicting outcome in melanoma: where are we now? Br. J. Dermatol. 161, 496 503.
17. Koch, S.E. Lange, J.R. (2000). Amelanotic melanoma: the great masquerader. J. Am. Acad. Dermatol. 42, 731 734.
18. Labarre, P., Papon, J., Moreau, M.F., Moins, N., Bayle, M., Veyre, A. Madelmont, J.C. (2002). Melanin affinity of N-(2-diethylaminoethyl)-4- iodobenzamide, an effective melanoma imaging agent. Melanoma Res. 12, 115 121.
19. Lambert, B. Van De Wiele, C. (2005). Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 32, 980 989.
20. Lazova, R., Klump, V. Pawelek, J. (2010). Autophagy in cutaneous malignant melanoma. J. Cutan. Pathol. 37, 256 268.
21. Leboit, P.B.G., Weedon, D. Sarazin, A. (2006). Pathology and Genetics of Skin Tumours (Lyon : IARC Press).
22. Link, E.M. (1999). Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Hybridoma 18, 77 82.
23. Lorimore, S.A. Wright, E.G. (2003). Radiation-induced genomic instability and bystander effects: related inflammatory-type responses to radiation-induced stress and injury? A review. Int. J. Radiat. Biol. 79, 15 25.
24. Madelmont, J.C., Chezal, J.M., Moins, N., Teulade, J.C. Chavignon, O. (2008). Labelled analogues of halobenzamides as radio-pharmaceuticals. Patent WO 2008012782.
25. Mehrara, E., Forssell-Aronsson, E., Ahlman, H. Bernhardt, P. (2007). Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 67, 3970 3975.
26. Miao, Y. Quinn, T.P. (2008). Peptide-targeted radionuclide therapy for melanoma. Crit. Rev. Oncol. Hematol. 67, 213 228.
27. Miao, Y., Hylarides, M., Fisher, D.R., Shelton, T., Moore, H., Wester, D.W., Fritzberg, A.R., Winkelmann, C.T., Hoffman, T. Quinn, T.P. (2005). Melanoma therapy via peptide-targeted [alpha]-radiation. Clin. Cancer Res. 11, 5616 5621.
28. Miller, A.J. Mihm, M.C. Jr. (2006). Melanoma. N. Engl. J. Med. 355, 51 65.
29. Miot-Noirault, E., Papon, J., Gardette, M., Bonnet-Duquennoy, M., Labarre, P., Maisonial, A., Madelmont, J.C., Maublant, J., Chezal, J.M. Moins, N. (2009). The use of [(125)I] scintigraphic in vivo imaging in melanoma-bearing mice for a rapid prescreening of vectors to melanoma tissue. Cancer Biother. Radiopharm. 24, 629 636.
30. Moins, N., Papon, J., Seguin, H. et al. (2001). Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl. Med. Biol. 28, 799 808.
31. Nijsen, J.F., Krijger, G.C. Van Het Schip, A.D. (2007). The bright future of radionuclides for cancer therapy. Anticancer Agents Med. Chem. 7, 271 290.
32. Pham, T.Q., Berghofer, P., Liu, X., Greguric, I., Dikic, B., Ballantyne, P., Mattner, F., Nguyen, V., Loc'h, C. Katsifis, A. (2007). Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma. J. Nucl. Med. 48, 1348 1356.
33. Prota, G. (2000). Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. Pigment Cell Res. 13, 283 293.
34. Revskaya, E., Jongco, A.M., Sellers, R.S., Howell, R.C., Koba, W., Guimaraes, A.J., Nosanchuk, J.D., Casadevall, A. Dadachova, E. (2009). Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin. Cancer Res. 15, 2373 2379.
35. Sullivan, R.J. Atkins, M.B. (2009). Molecular-targeted therapy in malignant melanoma. Expert Rev. Anticancer Ther. 9, 567 581.
36. Sywak, M.S., Pasieka, J.L., Mcewan, A., Kline, G. Rorstad, O. (2004). 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J. Surg. 28, 1157 1162.
37. Tarhini, A.A. Agarwala, S.S. (2006). Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther. 19, 19 25.
38. Thompson, J.F., Scolyer, R.A. Kefford, R.F. (2005). Cutaneous melanoma. Lancet 365, 687 701.
39. Verburg, F.A., De Keizer, B., Lips, C.J., Zelissen, P.M. De Klerk, J.M. (2005). Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur. J. Endocrinol. 152, 33 37.
40. Welch, D.R., Bisi, J.E., Miller, B.E., Conaway, D., Seftor, E.A., Yohem, K.H., Gilmore, L.B., Seftor, R.E., Nakajima, M. Hendrix, M.J. (1991). Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int. J. Cancer 47, 227 237.